HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Eyal, S. Articles by Unadkat, J. D. Search for Related Content PubMed PubMed Citation Articles by Eyal, S. Articles by Unadkat, J. D.

Simultaneous PET Imaging of P-Glycoprotein Inhibition in Multiple Tissues in the Pregnant Nonhuman Primate

¹ Department of Pharmaceutics, University of Washington, Seattle, Washington; ² Division of Nuclear Medicine, University of Washington, Seattle, Washington; ³ University College Cork, Cork, Ireland; and ⁴ Departments of Pharmacy, Obstetrics and Gynecology, University of Washington, Seattle, Washington

Correspondence: Address correspondence to: Jashvant D. Unadkat, Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195. E-mail: jash{at}u.washington.edu

Studies in rodents indicate that the disruption of P-glycoprotein (P-gp) function increases drug distribution into the developing fetus and organs such as the brain. To simultaneously and serially evaluate the effect of P-gp activity and inhibition on the tissue distribution of drugs in a more representative animal model, we tested the feasibility of conducting whole-body PET of the pregnant nonhuman primate (Macaca nemestrina). We used ¹¹C-verapamil as the prototypic P-gp substrate and cyclosporine A (CsA) as the prototypic inhibitor. Methods: Four pregnant macaques (gestational age, 145–159 d; gestational term, 172 d) were imaged after the intravenous administration of ¹¹C-verapamil (30–72 MBq/kg) before and during intravenous infusion of CsA (12 or 24 mg/kg/h, n = 2 each). The content of verapamil and its metabolites in plasma samples was determined using a rapid solid-phase extraction method. The plasma and tissue time–radioactivity concentration curves of ¹¹C were integrated over 0–9 min after each verapamil injection. The tissue or arterial plasma area under the time–concentration curve (AUC_tissue/AUC_plasma) served as a measure of the tissue distribution of ¹¹C radioactivity. CsA effect on ¹¹C radioactivity distribution was interpreted as P-gp inhibition. The change in the fetal liver AUC ratio served as a reporter of placental P-gp inhibition. Results: CsA effect on tissue distribution of ¹¹C radioactivity (AUC ratios) did not increase with the mean blood concentration of CsA, indicating a near-maximal P-gp inhibition. CsA increased maternal brain and fetal liver distribution of ¹¹C radioactivity by 276% ± 88% (P < 0.05) and 122% ± 75% (P < 0.05), respectively. Changes in other measured tissues were not statistically significant. Conclusion: These data demonstrate for the first time, to our knowledge, the feasibility of simultaneous, serial, noninvasive imaging of P-gp activity and inhibition in multiple maternal organs and the placenta in the nonhuman primate. Our findings, consistent with previous data in rodents, indicate that the activity of P-gp in the placenta and the blood–brain barrier is high and that the inhibition of P-gp facilitates drug distribution across these barriers.

Key Words: P-glycoprotein • ¹¹C-verapamil • blood–brain barrier • cyclosporine A • pregnancy

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]